Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes
収録刊行物
-
- Ann Rheum Dis
-
Ann Rheum Dis 70 (12), 2095-2102, 2011